- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 1 | GlobeNewswire (USA) | ||
| 25.10. | vTv Therapeutics ends key license agreement with OnKure | 2 | Investing.com | ||
| 23.10. | OnKure files to sell 2.94M shares of Class A Common Stock for holders | 1 | Seeking Alpha | ||
| 10.10. | Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm | 1 | Benzinga.com | ||
| 10.10. | OnKure started at outperform by Oppenheimer, OKI-219 potential cited | 2 | Seeking Alpha | ||
| 10.10. | OnKure shares initiated with Outperform rating on drug potential | 1 | Investing.com | ||
| 08.10. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | OnKure and Reneo Pharmaceuticals complete merger | 2 | Pharmaceutical Technology | ||
| 04.10. | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 122 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
| 03.10. | Reneo Pharmaceuticals stockholders approve merger with OnKure | 1 | Seeking Alpha | ||
| 03.10. | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 112 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| 03.10. | Reneo Pharmaceuticals secures stockholder approval for OnKure merger | 4 | Investing.com | ||
| 02.10. | Reneo Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.09. | Reneo Pharmaceuticals executive buys over $76k in company stock | 2 | Investing.com | ||
| 17.09. | Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying | 2 | Benzinga.com | ||
| 13.09. | Reneo Pharmaceuticals kündigt Ausscheiden einer Führungskraft im Zuge der Fusion an | 2 | Investing.com Deutsch | ||
| 13.09. | Reneo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | Reneo Pharmaceuticals, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 19.08. | Reneo Pharmaceuticals, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 15.08. | Reneo Pharmaceuticals insider buys shares worth over $380k | 1 | Investing.com |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,965 | +0,15 % | Ihre wichtigsten Termine: Frische Q3-Zahlen von: Alphabet, Visa, PayPal, McDonald's, Pfizer und Lufthansa | © Foto: Rolf Vennenbernd/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:50... ► Artikel lesen | |
| INNOCAN PHARMA | 0,151 | +2,38 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 16,400 | +4,79 % | Assembly Biosciences - Herpes-Wirkstoff übertrifft Erwartungen | Mein diesjähriger Top-Favorit Assembly Biosciences (WKN: A402CB) präsentierte gestern herausragende Studiendaten seines Wirkstoffkandidaten ABI-5366 zur Behandlung von wiederkehrendem Genitalherpes.... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,125 | -0,53 % | Nektar Therapeutics: Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia | - Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) -
- Eight of nine patients achieved complete remission... ► Artikel lesen | |
| ALTIMMUNE | 6,315 | +1,58 % | Altimmune, Inc: Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program... ► Artikel lesen | |
| ROCKET LAB USA | 10,440 | -0,76 % | Could Rocket Lab Be a Millionaire-Maker Stock in the Trillion-Dollar Space Industry? | ||
| CORBUS PHARMACEUTICALS | 15,200 | -2,56 % | Corbus Pharmaceuticals-Aktie: Eine große Chance? | Es sind nur noch wenige Tage bis zur mit großer Spannung erwarteten US-Wahl. Wie ist vor dieser Entscheidung die Lage im Biotech-Sektor? Wie könnte es danach weitergehen? Bietet etwa eine Aktie wie... ► Artikel lesen | |
| TALPHERA | 0,827 | 0,00 % | Talphera, Inc.: Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit | The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites
Primary endpoint in the NEPHRO CRRT study is measured... ► Artikel lesen | |
| SOLIGENIX | 3,541 | 0,00 % | Pre-market Movers: AMTD Digital, Wheeler Real Estate Investment Trust, ALT5 Sigma, Fangdd Network, Soligenix | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green AMTD Digital Inc. (HKD) is up over 36% at $5.32.
Wheeler... ► Artikel lesen | |
| KALA BIO | 6,405 | +2,89 % | KALA BIO: Vorstandsmitglied tritt zurück | ||
| BRIDGEBIO PHARMA | 21,700 | -7,62 % | BridgeBio Pharma, Inc.: BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 | - Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to... ► Artikel lesen | |
| NEUROGENE | 45,440 | +3,25 % | Neurogene (NASDAQ:NGNE) Trading Down 3.7% - Here's What Happened | ||
| ACLARIS THERAPEUTICS | 1,822 | -5,33 % | Aclaris Therapeutics: +85% Gewinn für Anlegerclub NBC! | Der No Brainer Club (NBC) hat erneut bewiesen, warum er als der erfolgreichste Biotech-Anlegerclub Deutschlands gilt. Mit Aclaris Therapeutics (WKN: A1412H) konnten Mitglieder innerhalb weniger Monate... ► Artikel lesen | |
| BOIRON | 32,450 | +1,25 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,425 (-8,14 %) liegt der Kurs bei 16,075 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
